Tesla Stock Finally Responds to Clear Catalyst
Overall Thesis
Discussion of Moderna's cancer treatment breakthrough using mRNA technology and its potential implications for AI in medicine, with Tesla mentioned in the title but not substantively analyzed.
Narratives
The hosts discuss Moderna's mRNA cancer treatment breakthrough that reduced high-risk cancer recurrence, noting the stock roughly doubled to tripled on the news. They frame this as the start of a broader 'ChatGPT moment' for AI applied to medicine that could pull in massive R&D investment from big pharma.
Key Arguments
- Moderna's phase 3 trial showed a significant reduction in high-risk cancer recurrence using personalized mRNA treatment
- The stock roughly doubled/tripled on the announcement, implying a jump from a $50B to $100-120B market cap
- AI applied to medicine (imaging, biomarkers, drug design) could trigger a 'gold rush' and accelerate cures beyond current timelines
- Big pharma players like Roche/Genentech and Eli Lilly are only using a small fraction of available AI compute so far, implying room for growth
Predictions (1)
The hosts note Tesla stock popped about $15 in what they attribute to a delayed reaction to Sunday's Cybercab event, with investors realizing 'something's happening with CyberCab and Robotaxi.' They discuss infrastructure buildout (charging stalls in Austin) as evidence of robotaxi scaling but do not give a specific share price target.
Key Arguments
- Tesla stock rose roughly $15 in apparent delayed reaction to the Cybercab/Robotaxi news from the prior Sunday event
- Fear of missing out on Robotaxi progress is cited as the catalyst for the stock move
- Austin charging infrastructure build-out (80 stalls) is discussed as an early indicator of robotaxi fleet scaling, though this describes fleet size rather than share price
Hedges & Caveats
- Treatment reduces recurrence risk by 49%, not a cure
- Results based on high-risk population, not general population
- Clinical trials took 5+ years to complete
- Further improvements and applications still being developed
- Host explicitly states he was not in the stock before the announcement